ARIC

在过去的20年里，社区动脉粥样硬化风险（ARIC）研究提供了关于动脉粥样硬化及其进展的危险因素，冠心病和中风的危险因素以及社区心血管疾病发病率趋势的重要新信息。我们在此建议从2005年至2012年继续进行ARIC。每个ARIC现场中心、协调中心和实验室都有单独的提案。 我们响应ARIC RFP的更新目标是： 1.在四个ARIC社区完成23年的冠心病（CHD）监测，允许检测CHD发病率、病例死亡率和种族特异性亚组死亡率的趋势。2005-2009年，冠心病监测将扩大到75-84奥尔兹，并将进行住院心力衰竭（55岁及以上）和门诊心力衰竭监测（65岁及以上）。 2.对ARIC先前检查的心血管疾病（CVD）发病率和死亡率队列进行了23年的随访，以确定与CHD、卒中和2005-2009年心力衰竭事件相关的因素。 3.使用来自现有亚临床疾病病例、现有和新发生的心血管疾病病例和对照受试者以及亚临床疾病快速进展的亚组的储存血液、尿液和DNA样本，识别和表征心血管疾病的新型遗传和生化风险因素。将通过动脉粥样硬化和CVD的途径方法鉴定待测量的基因和分析物。 扩展将使ARIC能够继续（1）解决CVD的社区趋势，（2）利用其宝贵的数据库和生物样本资源来解决心血管疾病病因学的新问题。 协作研究协调中心一直担任ARIC协调中心（CC），并将继续为ARIC研究提供整体操作和科学协调，特别强调统计方法。CC的工作人员将参加所有的ARIC委员会和小组委员会，将协调电话会议和记录。协调委员会工作人员将作为主要作者和共同作者积极参与撰写稿件，并在需要时提供统计咨询、分析和审查。CC将维护并参与手册、表格和说明的制定。培训课程将由协调中心工作人员协调。将维护和创建HF的数据管理以及CHD和HF的死亡率和发病率分类（MMCC），包括数据输入系统和准备分析数据文件的系统。MMCC的所有活动将由CC协调。将编写质量控制报告，并将继续对外地中心和中央机构进行监测访问。当问题出现时，CC将响应社区监测（CHD和HF）、AFU和实验室研究（包括病例队列研究）的需求。CC将维护和更新ARIC的两个网站。CC将协调ARIC的努力，向ARIC科学家内外的调查人员传播数据。

Over the past 20 years, the Atherosclerosis Risk In Communities (ARIC) Study has provided important new information on risk factors for atherosclerosis and its progression, on risk factors for coronary heart disease and stroke, and on trends in community rates of cardiovascular disease. We herein propose continuation of ARIC from 2005 to 2012. There are separate proposals for each ARIC Field Center, the Coordinating Center, and the Laboratories. Our aims for renewal in response to the ARIC RFPs are: 1. Completion of 23 years of coronary heart disease (CHD) surveillance in the four ARIC communities, permitting detection of trends in CHD Incidence, case fatality, and mortality in racesex-specific subgroups. For 2005-2009, CHD Surveillance will expand to 75-84 year olds, and inpatient heart failure (55 years and older) and outpatient heart failure surveillance (65 years and older) will be undertaken. 2. Follow-up of ARIC's previously examined cohort for cardiovascular disease (CVD) morbidity and mortality over 23 years, to identify factors related to Incident CHD, stroke, and for 2005-2009, heart failure. 3. Identification and characterization of novel genetic and biochemical risk factors for CVD using stored blood, urine, and DNA samples from available subclinical disease cases, available and newly-occurring CVD cases and control subjects, and subgroups with rapid progression of subclinical disease. The genes and analytes to be measured will be identified via a pathway approach to atherosclerosis and CVD. An extension will enable ARIC to continue to (1) address community trends in CVD and (2) make use of its valuable database and biosample resource to address new questions on the etiology of cardiovascular disease. The Collaborative Studies Coordinating Center has served as the ARIC coordinating center (CC) and will continue providing the overall operation and scientific coordination for the ARIC study with special emphasis on statistical methodology. CC staff will participate in all the ARIC committees and subcommittees, will coordinate conference calls and take minutes. The CC staff will actively participate in writing manuscripts as lead and co-authors and provide statistical advice, analyses and review when needed. The CC will maintain and participate in development of manuals, forms, and instructions. Training sessions will be coordinated by CC staff. Data management, including systems for data entry and systems to prepare data files for analyses, will be maintained and created for HF and mortality and morbidity classification (MMCC) for CHD and HF. All MMCC activities will be coordinated by CC. Quality control reports will be prepared and monitoring visits to field centers and central agencies will be on going. The CC will respond to needs of community surveillance (CHD and HF), AFU, and laboratory studies (including case-cohort studies) as issues arise. The CC will maintain and update two websites for ARIC. The CC will coordinate ARIC's efforts to disseminate data to investigators within and outside the ARIC scientists.